The FDA has received 3,248 adverse event reports for cats that name Esafoxolaner.
- 3,248 reports name Esafoxolaner in cats, which is 2.1% of all 151,164 cat reports. A report counts under every active ingredient it names.
- 15% are marked serious and 7.9% record a death or euthanasia; across all cat reports those figures are 27% and 9.4%.
- 21% are complaints that the product did not work (19% across all cat reports).
- The clinical signs reported most are lethargy, vomiting and application site hair loss.
- The FDA lists 1 approved animal drug application containing Esafoxolaner for cats, the earliest approved in 2023.
- None of this is a rate. The FDA data does not record how many cats were given Esafoxolaner, so it cannot say how often any of this happens.
How the reports break down
| What the reports say | Reports | Share of this medicine's reports | All cat reports |
|---|---|---|---|
| Marked seriousthe FDA record flags the report as serious | 481 | 15% | 27% |
| Death or euthanasiathe outcome recorded in the report, with no finding of cause | 258 | 7.9% | 9.4% |
| Did not worka complaint that the product failed to work, which the FDA files as an adverse event | 674 | 21% | 19% |
| Seizurea seizure or convulsion is among the clinical signs | 144 | 4.4% | 2.6% |
| Not used per labelthe report says the product was not used the way its label directs | 549 | 17% | 33% |
Where on the body do the reported signs sit?
Not on the body: Whole body 17% Did not work 12% How it was given 5.2%
- Stomach and gut35%vomiting, hypersalivation, foaming at the mouth, drooling and 3 more
- Whole body17%lethargy, death by euthanasia, death
- Did not work12%lack of efficacy (ectoparasite) - flea, lack of efficacy (endoparasite) - roundworm, lack of efficacy (endoparasite) - tapeworm
- Brain and nerves9.8%ataxia, seizure, tremor
- Where it was applied8.9%application site hair loss, licking at application site
- Behaviour7.4%hiding, behavioural disorder, vocalisation
- How it was given5.2%accidental exposure, incorrect route of drug administration
- Eyes2.2%dilated pupils
- Blood and organ tests1.9%hyperglycaemia
Each figure is a share of sign mentions among the 25 signs reported most for Esafoxolaner in cats. One report can list several signs, so these do not add up to reports. The grouping into body systems is ours; the signs in each group are listed beside it.
Clinical signs reported most
- Lethargy528 16%
- Vomiting414 13%
- Application site hair loss296 9.1%
- Hypersalivation290 8.9%
- Foaming at the mouth255 7.8%
- Drooling218 6.7%
- Not eating217 6.7%
- Lack of efficacy (ectoparasite) - flea213 6.6%
Reports received per year
Is it approved for cats?
The FDA lists 1 approved animal drug application containing Esafoxolaner for cats, the earliest approved in 2023.
| Product | Form | Approved for | First approved | FDA application |
|---|---|---|---|---|
| Nexgard ComboBoehringer lngelheim Animal Health USA, Inc. | Topical Solution RX | Cat | 2023 | 141-570 |
What can you do next?
Report counts: FDA Center for Veterinary Medicine adverse event reports, read 11 November 2026 (FDA data last updated 5 October 2026). Approvals: Animal Drugs @ FDA, read 11 November 2026. Counts are reports, not animals and not doses.
Where can you go from this result?
This result is one of 94 in the lookup. Open it in the lookup to set it beside another medicine, or read how the counts were collected.
- Robenacoxib in cats3,276
- Cyclosporine in cats3,030
- Amoxicillin in cats2,970
- Dexmedetomidine in cats2,862
To report a suspected side effect in your own animal, follow how to report an animal drug side effect to the FDA. The FDA explains what a report can and cannot show in openFDA's guide to reading the results.
Compiled by Vincent Wesley Couey, PetMaxxing Research (ORCID 0009-0005-6869-308X). Sources: openFDA animal and veterinary adverse event interface; Animal Drugs @ FDA.